Earning Analysis
Welcome to our in-depth analysis of Thermo Fisher Scientific Inc(TMO) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Thermo Fisher Scientific Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-10-22 | Pre-Market | 5.50 | 5.79 | +5.27 | 10.91B | 11.12B | +1.90 | +1.65 | +1.04 |
| FY2025Q2 | 2025-07-23 | Pre-Market | 5.22 | 5.36 | +2.68 | 10.68B | 10.86B | +1.62 | +9.14 | +13.41 |
| FY2025Q1 | 2025-04-23 | Pre-Market | 5.10 | 5.15 | +0.98 | 10.23B | 10.36B | +1.27 | -0.71 | -3.08 |
| FY2024Q4 | 2025-01-30 | Pre-Market | 5.93 | 6.10 | +2.87 | 11.28B | 11.40B | +1.03 | +6.78 | +2.49 |
| FY2024Q3 | 2024-10-23 | Pre-Market | 5.25 | 5.28 | +0.57 | 10.63B | 10.60B | -0.35 | -1.69 | -6.58 |
| FY2024Q2 | 2024-07-24 | - | 5.13 | 5.37 | +4.68 | 10.52B | 10.54B | +0.22 | +4.07 | +11.38 |
| FY2024Q1 | 2024-04-24 | - | 4.70 | 5.11 | +8.72 | 10.18B | 10.35B | +1.67 | +0.49 | -1.02 |
| FY2023Q4 | 2024-01-31 | - | 5.64 | 5.67 | +0.53 | 10.73B | 10.89B | +1.43 | -4.96 | -1.21 |
| FY2023Q3 | 2023-10-25 | - | 5.58 | 5.69 | +1.97 | 10.64B | 10.57B | -0.58 | -5.47 | -2.94 |
| - | 2023-07-26 | - | 5.43 | 5.15 | -5.16 | - | - | - | +0.61 | -4.39 |
TMO Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Thermo Fisher Scientific Inc reported performance for FY2025Q3, announced on 2025-10-22. The company achieved an EPS of 5.79, compared to analyst estimates of 5.50 by 5.27% . Revenue for the quarter reached 11.12B compared to expectations of 10.91B by 1.90% .
The stock price reacted with a 1.65% one-day change and a 1.04% five-day change following the earnings release. These movements reflect market reaction in Thermo Fisher Scientific Inc growth trajectory and strategic initiatives.
TMO Earnings Forecast
Looking ahead, Thermo Fisher Scientific Inc(TMO) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 11.95B and an EPS of 6.45.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 0.84%, while EPS estimates have been Revise Upward by 1%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 1.49% . These revisions correlate with a 16.78% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Thermo Fisher Scientific Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between TMO's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+0.84%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+1.49%
In Past 3 Month
Stock Price
Go Up
+16.78%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:44.26B
--
EPS Estimate-Annual FY 2025:22.73
—
Stock Price575.24
TMO Revenue and EPS Performance: A Historical Perspective
Thermo Fisher Scientific Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-10-22,Pre-Market):
EPS: 5.79 (Actual) vs.5.50 (Estimate) (5.27%)
Revenue: 11.12B (Actual) vs. 10.91B (Estimate) (1.90%)
Price Reaction: 1.65%(1-Day), 1.04%(5-Day)
FY2025Q2 (2025-07-23,Pre-Market):
EPS: 5.36 (Actual) vs.5.22 (Estimate) (2.68%)
Revenue: 10.86B (Actual) vs. 10.68B (Estimate) (1.62%)
Price Reaction: 9.14%(1-Day), 13.41%(5-Day)
FY2025Q1 (2025-04-23,Pre-Market):
EPS: 5.15 (Actual) vs.5.10 (Estimate) (0.98%)
Revenue: 10.36B (Actual) vs. 10.23B (Estimate) (1.27%)
Price Reaction: -0.71%(1-Day), -3.08%(5-Day)
Earnings Reaction
The chart below shows how TMO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TMO sees a -2.54% change in stock price 10 days leading up to the earnings, and a -2.09% change 10 days following the report. On the earnings day itself, the stock moves by +0.99%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 0.83% on the day following the earnings release and then changed by 0.08% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Thermo Fisher Scientific Inc (TMO) Q3 2025 Earnings Call Summary
Positive
2025-10-22
Thermo Fisher's earnings call highlights strong financial performance, with increased revenue and EPS guidance for 2025 and expected organic growth acceleration in 2026-2027. Strategic M&A, cost management, and improved tariff situations are positive factors. The Q&A session reinforced confidence in growth, despite challenges in China. The overall sentiment is positive due to optimistic guidance and strategic initiatives, suggesting a likely stock price increase in the coming weeks.
Thermo Fisher Scientific Inc (TMO) Q2 2025 Earnings Call Summary
Positive
2025-07-23
The earnings call reveals strong financial performance with revenue and margin growth, positive biopharma trends, and strategic deals like the Sanofi acquisition. Despite challenges in China and academic sectors, management's optimism about long-term growth and share gains, alongside effective margin expansion strategies, suggests a positive outlook. The Q&A session reinforced confidence in growth, though some responses lacked detail. Overall, the company's strong position in biopharma and strategic initiatives indicate a likely positive stock price movement.
Thermo Fisher Scientific Inc (TMO) Q1 2025 Earnings Call Summary
Neutral
2025-04-24
The earnings call summary shows strong financial performance and a share repurchase program, indicating positive sentiment. However, the updated guidance reflecting tariff impacts and policy changes, combined with macroeconomic uncertainties, introduces caution. The Q&A reveals management's optimism but lacks clarity on long-term impacts, adding uncertainty. Overall, the positive and negative factors balance each other, leading to a neutral sentiment.
Thermo Fisher Scientific Inc (TMO) Q4 2024 Earnings Call Summary
Neutral
2025-01-30
Despite strong Q4 financial performance and shareholder returns, the guidance reflects modest growth expectations and challenges such as supply chain issues and pandemic revenue runoff. The Q&A revealed uncertainties in China and unclear management responses on policy impacts, which may temper investor optimism. The raised EPS guidance and revenue growth are offset by flat full-year performance and economic uncertainties, leading to a neutral sentiment.
Thermo Fisher Scientific Inc. (TMO) Q3 2024 Earnings Call Summary
Neutral
2024-10-23
The earnings call presents mixed signals. Financial performance is stable with flat revenue and slightly lower margins, but there's positive free cash flow and EPS beat. The Q&A highlights cautious optimism for biotech and future growth, but concerns about China and vague guidance impact sentiment. Share buybacks are positive, but overall guidance and market conditions suggest a neutral outlook.
Thermo Fisher Scientific Inc. (TMO) Q2 2024 Earnings Call Summary
Positive
2024-07-24
The earnings call summary and Q&A indicate a moderately positive outlook. Despite a slight revenue decline, the company reported strong financial metrics, including increased adjusted EPS, operating margins, and free cash flow. The raised 2024 revenue and EPS guidance, coupled with significant share buybacks and dividends, suggest confidence in future performance. However, challenges like foreign exchange impact and supply chain issues remain. The Q&A reflects cautious optimism, particularly regarding market recovery and China stimulus. Overall, the sentiment leans positive, likely resulting in a 2% to 8% stock price increase in the short term.
People Also Watch
FAQ
What were the key highlights of TMO’s latest earnings report for FY2025Q3?
How did TMO’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for TMO for 2025/Q4?
How does TMO’s stock price correlate with earnings forecast revisions?
What should investors expect from TMO’s next earnings report?